Juvenile Idiopathic Arthritis (JIA) Drug Development

Based on our leading-edge platforms and profound knowledge of autoimmune diseases, researchers from Creative Biolabs have earned a great reputation from our clients for superior custom drug development services. We offer a full range of juvenile idiopathic arthritis (JIA) drug development services to support our global clients with R&D, preclinical, and clinical development programs.

JIA is a rare and complex autoinflammatory disease of childhood associated with significant morbidity. JIA often persists into adulthood and can result in significant long-term morbidity, including physical disability. JIA is characterized by arthritis accompanied by high spiking fevers, plus a variety of additional features such as a typical rash, generalized lymphadenopathy, hepatosplenomegaly, and serositis.

Treatment of JIA

Historically, the management of JIA has relied on nonsteroidal medications with the slow addition of traditional disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate or sulfasalazine, and systemic corticosteroids. Patients with polyarticular and systemic JIA, however, often have disease refractory to traditional agents and/or face significant potential adverse effects.

The treatment of JIA has been revolutionized by the use of novel biologic agents that have much-improved short-term and long-term outcomes. Currently available biologic agents used to treat patients with JIA include tumor necrosis factor (TNF) blockers, various agents that target interleukin (IL)-1, IL-6 receptor, and T-cell and B-lymphocyte antigen.
The TNF inhibitors (TNFi) have shown tremendous benefit in children with polyarticular JIA and likely in enthesitis-related arthritis and psoriatic JIA as well. Five TNFi are commercially available, of which monoclonal antibodies against TNF have been extensively used in children with JIA.
The use of an anti-IL-1 or anti-IL-6 therapy has been reported to result in a dramatic improvement in some patients with JIA. It has specifically approved two medications for the treatment of systemic JIA.
With few exceptions, the studies have demonstrated that biologics are highly effective and safe in the treatment of JIA, and have propelled us into a new era of management. However, there are still subsets of JIA patients who fail to achieve disease control with any combination of medications. For certain of these patients, autologous stem cell transplantation (ASCT) may provide an option for disease remission.

Custom Services for JIA Drug Development

With the advent of novel biologic therapeutics, there has been a rapid increase in the number of and types of agents available for the treatment of JIA. As a top-ranking provider in the drug development market, Creative Biolabs offers various platforms to deal with the urgent demands for autoimmune diseases such as JIA, including but not limited to:

Monoclonal Antibody Development for JIA
Bispecific Antibody Development for JIA
Cell-based Therapy for JIA

Based on our years of experience and the most devoted scientists, Creative Biolabs has gained significant knowledge in JIA drug development. We are confident to deliver you the most suitable solution that can meet your specific requirements. Please feel free to contact us. We look forward to discussing your inquiry and finding the best solution for your needs.

Reference

Dewitt, E.M.; et al. Consensus treatment plans for new‐onset systemic juvenile idiopathic arthritis. Arthritis care & research. 2012, 64(7): 1001-1010.

For Research Use Only | Not For Clinical Use

Online Inquiry

Autoimmune Diseases

Contact us USA

Location:
Call:
Fax:
Email:

Location:
Call:
Email:

Germany

Location:
Call:
Email: